MktsMarkets

Lipocine Inc.
NASDAQ: LPCNKey statistics
LPCN News
Stories mentioning LPCN from around the web — every one is an open thread, so give it a like or add your take.
Loading news…
Financial statements
As filed, straight from the 10-Q — up to 19 years of history, free, with every line item chartable.
| Line item | Q1 '26Mar 31 | Q4 '25Dec 31 | Q3 '25Sep 30 | Q2 '25Jun 30 | Q1 '25Mar 31 | Q4 '24Dec 31 | Q3 '24Sep 30 | Q2 '24Jun 30 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 119.00 | 1,145 | 115.00 | 623.00 | 94.00 | 90.00 | ||
| Cost of Goods Sold | ||||||||
| Gross Profit | 0.00 | |||||||
| Operating Expenses | ||||||||
| Research & Development | 2,764 | 2,677 | 2,708 | 2,137 | 1,062 | 1,073 | 1,585 | 1,875 |
| Sales General & Admin | ||||||||
| Total Operating Expenses | 3,969 | 3,661 | 3,476 | 3,027 | 2,184 | 1,946 | 2,630 | 3,382 |
| Operating Income (Loss) | (3,849) | (2,516) | (3,361) | (2,404) | (2,090) | 1,545 | (2,630) | (3,293) |
| Interest Income | 178.00 | 145.00 | 174.00 | 199.00 | 226.00 | 233.00 | 274.00 | 309.00 |
| Interest Expense | ||||||||
| Other Expense | ||||||||
| Pretax Income | (3,672) | (2,369) | (3,187) | (2,206) | (1,865) | 1,782 | (2,219) | (3,068) |
| Tax Provision | 0.00 | 0.00 | ||||||
| Net Income (Loss) | (3,672) | (2,370) | (3,187) | (2,206) | (1,865) | 1,782 | (2,219) | (3,069) |
| Earnings Per Share (Basic) | (0.54) | (0.43) | (0.59) | (0.41) | (0.35) | 0.33 | (0.41) | (0.57) |
| Earnings Per Share (Diluted) | (0.54) | (0.42) | (0.59) | (0.41) | (0.35) | 0.33 | (0.44) | (0.56) |
| Weighted Average Shares Outstanding (Basic) | 6,795 | 5,449 | 5,413 | 5,352 | 5,349 | 5,339 | 5,348 | 5,344 |
| Weighted Average Shares Outstanding (Diluted) | 6,795 | 5,708 | 5,413 | 5,352 | 5,349 | 5,423 | 5,348 | 5,344 |
Scroll the table sideways for older periods — the line-item column and the period header stay put. Hover a row and use the chart handle to plot it over the full history.
About LPCN
Lipocine Inc. (NASDAQ: LPCN) is a stock listed on the Nasdaq Stock Market under the ticker symbol LPCN. It last traded at $1.48 (Nov 20, 2026, 4:00 PM ET), down 1.3% on the day. That gives Lipocine a market capitalisation of $16.6M.
Over the past 52 weeks LPCN has traded between $1.36 and $12.37.
Revenue for the quarter ended Mar 31, 2026 was $119.0K; a net loss of $3.7M. Revenue was up 26.6% from $94.0K in the quarter ended Mar 31, 2025.
| Quarter ended | Revenue | Net income | Margin |
|---|---|---|---|
| Mar 31, 2026 | $119.0K | -$3.7M | -3085.7% |
| Dec 31, 2025 | $1.1M | -$2.4M | -207.0% |
| Sep 30, 2025 | $115.0K | -$3.2M | -2771.3% |
| Jun 30, 2025 | $623.0K | -$2.2M | -354.1% |
From Lipocine’s quarterly (10-Q) filings, in US dollars.
Take a break — play a market game
Seven free games built around the markets. No download, no sign-up: they run right here in your browser.
Latest News
Market news from around the web — every story is an open thread, so give it a like or add your take.
Loading news…